Title: Differential effects of voclosporin and tacrolimus on insulin secretion from human islets

Authors: Jelena Kolic¹, Leanne Beet¹, Peter Overby¹, Haoning Howard Cen¹, Evgeniy Panzhinskiy¹, Daren R. Ure², Jennifer L. Cross³, Robert B. Huizinga³, James D. Johnson¹*

Affiliations:

¹ Diabetes Research Group, Life Sciences Institute, Department of Cellular and Physiological Sciences & Department of Surgery, University of British Columbia, Vancouver, Canada, V6T 1Z3.
² Hepion Pharmaceuticals, Edmonton, Alberta, Canada, T6N 1H1
³ Aurinia Pharmaceuticals, Victoria, British Columbia, Canada, V8Z 7X8.

*Address correspondence to: Professor James D. Johnson, PhD., Faculty of Medicine, Department Cellular and Physiological Sciences, The University of British Columbia, Life Sciences Institute, 5358 – 2350 Health Sciences Mall, Vancouver, British Columbia, Canada, V6T 1Z3. Phone: 604 822 7187, Email: James.d.johnson@ubc.ca, Twitter: @JimJohnsonSci

Short title: Voclosporin versus Tacrolimus on Insulin Release

Keywords: immunosuppressant, insulin secretion, diabetes, organ transplantation

Declaration of Interests: JLC and RBH are employees of Aurinia Pharmaceuticals. JDJ has received research support to his lab to support this project. There are no other conflicts of interest to disclose.

Funding: Research was supported by a research contract from Aurinia Pharmaceuticals to J.D.J.
Abstract

Context. The incidence of new onset diabetes after transplant (NODAT) has increased over the past decade, likely due to calcineurin inhibitor-based immunosuppressants, including tacrolimus (TAC) and cyclosporin (CsA). Voclosporin (VCS), a next generation calcineurin inhibitor is reported to cause fewer incidences of NODAT but the reason is unclear.

Objective. Whilst calcineurin signaling plays important roles in pancreatic β-cell survival, proliferation, and function, its effects on human β-cells remain understudied. In particular, we do not understand why some calcineurin inhibitors have more profound effects on the incidence of NODAT.

Methods. We compared the effects of TAC and VCS on the dynamics of insulin secretory function, programmed cell death rate, and the transcriptomic profile of human islets. We studied two clinically relevant doses of TAC (10 ng/ml, 30 ng/ml) and VCS (20 ng/ml, 60 ng/ml), meant to approximate the clinical trough and peak concentrations.

Results. TAC, but not VCS, caused a significant impairment of 15 mM glucose-stimulated and 30 mM KCl-stimulated insulin secretion. This points to molecular defects in the distal stages of exocytosis after voltage-gated Ca\(^{2+}\) entry. No significant effects on islet cell survival or total insulin content were identified. RNA sequencing showed that TAC significantly decreased the expression of 17 genes, including direct and indirect regulators of exocytosis (SYT16, TBC1D30, PCK1, SMOC1, SYT5, PDK4, and CREM), whereas VCS has less broad and milder effects on gene expression.

Conclusions. Clinically relevant doses of TAC, but not VCS, directly inhibit insulin secretion from human islets, likely via transcriptional control of exocytosis machinery.
Introduction

New onset diabetes after transplant (NODAT) is a clinical problem that has increased in incidence over the past decade. It is widely believed that NODAT is caused by exposure to steroids or high dose calcineurin inhibitors, including tacrolimus (TAC; also known as FK506) and cyclosporin (CsA) (1,2). These drugs are shown to damage cell types critical for the maintenance of glucose homeostasis, particularly pancreatic β-cells (3). TAC is a mainstay for prevention of transplant rejection, but effective immunosuppression targeting a concentration range of 4-11 ng/mL still results in NODAT in > 20% of patients (1). There is an unmet clinical need for calcineurin inhibitors that do not cause diabetes in this already vulnerable patient population.

Voclosporin (VCS) is a next-generation calcineurin inhibitor that is structurally related to cyclosporine A (CsA) with the addition of a carbon molecule at amino acid-1 of CsA. This modification results in enhanced binding of the VCS-cyclophilin complex to calcineurin and shifts metabolism, resulting in increased potency and a consistently better pharmacokinetic-pharmacodynamic profile as compared to CsA. VCS was previously evaluated in a Phase IIb, multi-center, open-label, concentration-controlled study in patients undergoing de novo renal transplantation, evaluating the efficacy and safety of three doses of VCS (0.4, 0.6, and 0.8 mg/kg BID) as compared to TAC (4). In that study, the low-dose VCS group had similar efficacy to tacrolimus in controlling acute rejection with a significantly decreased incidence of NODAT (1.6% vs. 16.4%, respectively, p=0.031) (4). In the AURA study for lupus nephritis, 1.1% of patients receiving VCS (23.7 mg) and 1.1% of patients in the placebo group reported diabetes (5), contrasting with NODAT in 25.7% of patients while taking a standard dose of TAC for 1 year (6). Thus, there is an unexplained difference between the clinical diabetes seen after treatment with VCS, and currently prescribed immunosuppressants, TAC and CsA.

While the etiology of NODAT is not well understood, calcineurin and nuclear factor of activated T-cells (NFAT) are involved in a number of cellular processes outside of immunosuppression, including direct roles in normal pancreatic β-cell development and physiology (7-9). For example,
Heit et al. reported that β-cell selective knockout of calcineurin in mice reduced functional β-cell mass and caused diabetes that could be rescued by over-expressing active NFATc1 (8). The effects of acute calcineurin inhibition on human and mouse islet function was previously investigated in a study by our group comparing clinically relevant concentrations of TAC, CsA, and rapamycin (7). *In vitro* experiments showed a direct decrease in β-cell function after only 24 hours of exposure to TAC (7). *In vivo* studies in mice from our group and others have shown that inhibition of the calcineurin pathway by TAC impairs the function of transplanted human islet grafts (7,10). Thus, while previous data from animal models and human islets studies clearly demonstrates that TAC has multiple pathological effects on pancreatic islets, the mechanisms by which TAC impairs insulin secretion from human islets remained unresolved. Most importantly, there are no published studies directly comparing the direct effects of TAC versus VCS on human islets.

Here, we directly tested the hypothesis that VCS has lower human β-cell toxicity compared with TAC, and we conducted studies designed to investigate the molecular mechanisms involved (Fig 1A). We found that human islets exposed to TAC exhibited significantly reduced distal steps of glucose-stimulated insulin secretion, while VCS showed no statistically significant inhibition at a dose that elicits sufficient immunosuppression. RNA sequencing showed that TAC, and to a lesser extent VCS, decreased the expression of genes that specifically regulate the distal steps of insulin secretion. In support of the clinical observations, our data suggest that VCS is less toxic to human pancreatic β-cells at clinically relevant doses.

**Methods**

*Human islet culture*

High-quality research specific human islets from cadaveric donors were obtained from IsletCore Laboratory in Edmonton Alberta (11), and used under ethical approval from the UBC
Clinical Research Ethics Board (H13-01865). Islets were shipped in CMRL media (Thermo Fisher Scientific) overnight from Edmonton to the University of British Columbia. Upon arrival, islets were immediately purified by handpicking under a stereomicroscope and suspended in RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 5.5 mmol glucose, 10% FBS, and 100 units/ml penicillin/streptomycin. Groups of 100 islets were placed in non-treated 100-mm polystyrene petri dishes (Fisher Scientific) followed by 48-hr incubation at 37°C and 5% CO₂ (Fig. 1A). We chose 48-hr as an incubation time to balance our efforts to model long-term (years) exposure to these drugs in the clinical setting with our experience that human islet function degrades after 4-5 days in culture. Donor and isolation characteristics can be found in Figure 1B.

**Immunosuppression-related assays**

The Calcineurin inhibitor assay and the T-cell proliferation assay are described in more detail elsewhere (12,13). Briefly, peripheral blood mononuclear cell (PBMC) lysates were used in the calcineurin assay after 25 min stimulation with PMA-A23187. After lysis with a calcineurin assay buffer (no detergents) and 3 freeze-thaw cycles, the soluble fraction was probed by Western blot with 1:200 anti-NFAT2 antibody (Santa Cruz Biotechnology Cat# sc-13033, RRID:AB_2152501). Western blot analysis of NFAT accumulation after treatment with indicated doses of VCS and TAC was then conducted to identify the relative concentrations that elicited a similar response.

**Dynamic analysis of insulin secretion from human islets**

To define the dynamic effects of VCS and TAC on insulin secretion from human islets, we used human islet perifusion studies (7). We assessed the effects of TAC (10 ng/ml, 30 ng/ml) and VCS (20 ng/ml, 60 ng/ml) on the dynamics of insulin secretion in response to two stimuli that are diagnostic of changes in metabolism/signalling or exocytosis. Our standard approach (7,14-19) compared the response to 15 mM glucose stimulation and direct depolarization with 30 mM KCl. More specifically, 65 islets per column were perifused (0.4 ml/min) with 3 mM glucose KRB
solution as described previously (7) for 60 min to equilibrate the islets to the KRB and flow rate, and then with the indicated condition (as described in corresponding figure legends). First phase insulin release was defined as the amount of insulin secreted during the first 20 min of 15 mM glucose stimulation, while the remaining 40 of stimulation were defined as second phase. DMSO, VCS and TAC were present at the indicated concentrations during the entirety of the perifusion experiment. We repeated this experiment on islets from 17 donors to take into account the significant variability between human islet preparations (11). Samples were stored at −20 °C and insulin secretion was quantified using human insulin radioimmunoassay kits (Cedarlane).

Cell death assays

Pancreatic islets from human cadaveric donors were dispersed and seeded into 384-well plates and cultured in similar manner as previously described (20-23). Cells were stained with 50 ng/mL Hoechst 33342 (Invitrogen) and 0.5 μg/mL propidium iodide (PI) (Sigma-Aldrich) in RPMI 1640 medium (Invitrogen) with 5 mM glucose (Sigma-Aldrich), 100 U/mL penicillin, 100 μg/mL streptomycin (Invitrogen), 10% vol/vol fetal bovine serum (FBS) (Invitrogen) with or without a cytokine cocktail (25 ng/mL TNF-α, 10 ng/mL IL-1β, and 10 ng/mL IFN-γ; R&D Systems). We have previously shown that neither of these chemicals affect islet cell viability on their own at these concentrations (23). After 2 hours of staining, cells were incubated with different concentrations of VCS or TAC (1, 10, 20, 30, 60, 120 ng/ml) or vehicle (DMSO) and with a cytokine cocktail (25 ng/mL TNF-α, 10 ng/mL IL-1β, and 10 ng/mL IFN-γ; R&D Systems). Immediately after the addition of the test drugs, the cells were imaged at 37°C and 5% CO2. Images were captured every second hour for 48 hours using a robotic microscope (ImageXpress MICRO XLS, Molecular Devices) and analyzed using MetaXpress multi-wave cell score Software (Molecular Devices). To adjust for the difference in basal cell death for each individual run, each timepoint was normalized to the first timepoint then further normalized to the cytokine control.
RNA-sequencing and pathway analysis

Groups of 200 islets from 7 independent donors were treated for 48 hours with vehicle (DMSO), TAC (30 ng/ml) or VCS (60 ng/ml) then immediately flash-frozen in liquid nitrogen and stored at -80°C. RNA isolation, library preparation, RNA sequencing and bioinformatics support were provided by the UBC Biomedical Research Centre Core Facility. Briefly, sample quality control was performed using the Agilent 2100 Bioanalyzer. Qualifying samples were then prepped following the standard protocol for the NEBnext Ultra ii Stranded mRNA (New England Biolabs). Sequencing was performed on the Illumina NextSeq 500 with Paired End 42bp × 42bp reads. Demultiplexed read sequences were then aligned to the reference sequence using STAR aligners (STAR, RRID:SCR_015899) Assembly were estimated using Cufflinks (Cufflinks, RRID:SCR_014597) through bioinformatics apps available on Illumina Sequence Hub. Raw counts were analyzed by NetworkAnalyst 3.0 (www.networkanalyst.ca) (24). DeSeq package was selected for differential expression of the genes. Differentially expressed genes were identified as those with an adjusted \( p \) value < 0.05 using the comparison of TAC vs DMSO or VCS vs DMSO.

To determine the relationship between the differentially expressed genes and the calcineurin-NFAT pathway, we extracted all 49 genes in the Gene Ontology Term “calcineurin-NFAT pathway” (accessed July 30, 2020 from http://www.informatics.jax.org/vocab/gene_ontology/GO:0033173). We removed genes from the calcineurin-NFAT list without human homologues and that were not expressed in our human islet RNAseq. We then combined the expressed calcineurin-NFAT list with the genes that were differentially expressed between DMSO and TAC and used the protein-protein network interaction analysis tools at string-db.org with the following setting (active interaction sources – all; medium confidence 0.4; max interactors 0).

Statistics and data analysis

Data were analyzed using a one-way multiple comparisons ANOVA followed by a post hoc t-test using the Tukey HSD method, unless otherwise indicated. Data are expressed as means ±
SEM, and $p < 0.05$ was considered significant. $n$ values represent the number of unique islet donors studied.

**Results**

**Effects of TAC and VCS on NFAT activity**

Both TAC and VCS exert their immunosuppressive effects through inhibition of calcineurin phosphatase activity, preventing the dephosphorylation and activation of NFATc (25,26). Each of these two drugs is distinct with regard to its molecular mechanism of action. TAC interacts with the immunophilin FKBP12 prior to binding calcineurin, whereas VCS interacts with cyclophilins. The *in vitro* activity of TAC, VCS (and the structurally related inhibitor CsA) were compared in a calcineurin inhibition assay and for their downstream ability to inhibit the division of activated T cells. The IC$_{50}$ of TAC against calcineurin was found to be approximately 4-fold lower than VCS, in accordance with clinical dosing where the therapeutic range of TAC is 5-30 ng/mL and VCS target trough concentrations are around 20-60 ng/mL (Fig. 2A). Surprisingly, the potency difference between TAC and VCS widened to 50-fold, in favor of TAC, when looking at inhibition of T-cell proliferation (Fig 2A), leading to additional experiments comparing the impact of each drug on their common pathway effector, NFAT. Maximal activation of NFAT was observed at 56 ng/mL of VCS and only 1.4 ng/mL of TAC, a potency difference of 40-fold (Fig. 2B,C,D). These data demonstrate that, at therapeutic concentrations, TAC has a far more profound impact on NFAT than VCS (Fig. 2E).

**Effects of TAC or VCS on basal and glucose stimulated insulin secretion**

Insulin is released from pancreatic islets, *in vivo* and *in vitro*, in a biphasic pattern that includes both a rapid 1st phase of pre-docked insulin granules and a 2nd sustained phase involving granules that are recruited to the plasma membrane (27). There is significant inter-individual variability in the rate of insulin secretion from human islets (11) and the effects of immunosuppressants (7),
so we examined insulin secretion from high quality human islets isolated from 17 donors exclusively for research purposes. We employed the dynamic perifusion system with frequent sampling to evaluate basal insulin secretion at 3 mM glucose, both phases of insulin secretion during 15 mM glucose stimulation, and insulin secretion in response to direct depolarization with 30 mM KCl. TAC at 10 ng/ml (clinical trough) and 20 ng/ml (clinical peak) significantly inhibited total insulin secretion at 15 mM glucose, whereas VCS did not (Fig. 3A,B). TAC exhibited a specific effect on the 2nd phase but not the 1st phase of glucose-stimulated insulin secretion (Fig. 3C,D). The insulin secretory response to 30 mM KCl was also significantly inhibited by both concentrations of TAC (Fig. 3E). In contrast, VCS concentrations approximately 2 times higher than TAC had milder effects on glucose-stimulated insulin secretion. Specifically, the clinical trough concentration of 20 ng/ml VCS was ~50% less inhibitory to the total and 2nd phase of insulin secretion and did not result in statistically significant inhibition (Fig. 3A,B,D). No significant differences in basal insulin secretion were observed at 3 mM glucose for either drug at either of the concentrations tested (Fig. 3F). Similar results were observed when the perifusion data were normalized to basal insulin secretion (Fig. 3G,H). We were unable to detect significant differences in acid-ethanol extractable insulin protein content in human islets treated with either drug, at either concentration, for 48 hr (Fig. 4). These results indicate that the specific significant inhibitory effects of TAC on total and 2nd phase glucose-stimulated insulin secretion, as well as insulin secretion stimulated by direct depolarization, are likely to be direct effects on the exocytosis machinery rather than a result of reduced insulin production. Collectively, these data also demonstrate that VCS has milder effects on human islet secretory function when compared with TAC in this sensitive in vitro assay system.

Effects of TAC or VCS on human islet cell survival

We next assessed the effects of TAC and VCS on the survival of dispersed human islet cells using our long-term high-content imaging protocols that measure both apoptotic and non-
apoptotic cell death over multiple days of culture in the presence of proinflammatory cytokines (20-23) (Fig. 5A,B). We studied both TAC and VCS over a 5 point-dose response curve. We observed no significant differences in human islet cell survival following either drug treatment (Fig. 5C). This is consistent with our data showing no changes in insulin content following 48 hrs of drug treatment, further pointing to the primacy of the direct effect of TAC on insulin secretion.

**Effects of TAC or VCS on human islet gene expression**

In order to provide clues as to the underlying molecular mechanisms by which TAC, but not VCS, significantly inhibits insulin secretion we performed RNAseq and network analysis on human islets from 7 donors (Fig 1B). Despite significant donor to donor variation in gene expression, we were able to identify multiple significantly differentially expressed genes in human islets treated with these immunosuppressant drugs, compared to DMSO (Fig. 6A). Specifically, TAC significantly decreased the expression of synaptotagmin 16 (SYT16), TBC1 domain family member 30 (TBC1D30), phosphoenolpyruvate carboxykinase 1 (PCK1), SPARC related modular calcium binding 1 (SMOC1), synaptotagmin 5 (SYT5), muscular LMNA interacting protein (MLIP), coiled-coil domain containing 184 (CCDC184), ankyrin repeat and SOCS box containing 4 (ASB4), pyruvate dehydrogenase kinase 4 (PDK4), long intergenic non-protein coding RNA 473 (LINC00473), long intergenic non-protein coding RNA 602 (LINC00602), SLC8A1 antisense RNA 1 (SLC8A1-AS1), leucine rich repeat LGI family member 2 (LGI2), islet amyloid polypeptide (IAPP), cAMP responsive element modulator (CREM), B9 domain containing 1 (B9D1), and scavenger receptor class B member 2 (SCARB2). VCS only significantly decreased the expression of SYT16, TBC1D30, and PCK1, and to a qualitatively lesser degree.

Next, we examined the relationship between the calcineurin-NFAT gene network, as defined by its Gene Ontology term, and the TAC-modulated genes in human islets using single String protein-protein interaction network modelling (Fig. 6B). These analyses showed that CREM was the TAC-target mostly highly connected to calcineurin-NFAT network, with highest confidence-
level interactions with NFATC1, NFATC2, and NFATC3, and a medium confidence link to GSK3B. MILP showed high confidence interactions with a module including Cardiomyopathy Associated 5 (CMYA5) and Myozenin 2 (MYOZ2). PCK1 showed a medium confidence interaction with GSK3B. PDK4 showed a high confidence interaction with MTOR, and also with PCK1.

We found medium confidence interactions between SMOC1 and Leucine Rich Repeat LGI Family Member 2 (LGI2), between B9D1 and Mitogen-Activated Protein Kinase 7 (MAPK7), and between IAPP and Prion Protein (PRNP). Together, these analyses show how VCS and TAC treatment affect the expression of specific genes via calcineurin signalling and lead us to our current working model (Fig. 7C).

Discussion

The effects of calcineurin inhibitors on human β-cells remain understudied. A deeper understanding of how immunosuppressive agents affect human islets is necessary to elucidate the pathogenesis of NODAT and to identify immunosuppressants with improved safety profiles. Thus, the objective of the present study was to determine why the next-generation calcineurin inhibitor, VCS, has lower human β-cell toxicity compared with TAC. To examine this, we compared the effects of TAC and VCS on the dynamics of insulin secretory function, the programmed cell death, and the transcriptomic profile of isolated human islets. We found that TAC, but not VCS, caused a significant impairment of both 15 mM glucose and 30 mM KCl-stimulated insulin secretion at clinically relevant doses. We saw no effect on total insulin content or human islet cell survival with either drug. Gene pathway enrichment analysis of RNAseq data showed that TAC decreased the expression of genes that regulate exocytosis and genes that regulate transport from the ER to the Golgi apparatus. VCS treatment also induced these changes; however, it did so to a lesser extent. Thus, this greater inhibition of insulin secretion could provide an explanation of why the risk of NODAT is higher in patients taking TAC than the next generation calcineurin
inhibitor VCS. The equivalently immunosuppressive dose ranges of VCS and TAC we used have dramatically different potencies on NFAT, suggesting that NFAT-mediated gene expression mediates the observed effects on exocytosis regulating gene expression.

Previous studies have found that calcineurin inhibitors impair glucose-stimulated insulin secretion in rodent islets and rodent cell lines (8,28-39), although through mechanisms that we show here are not validated in human islets. For example, we do not see evidence for a robust effect of TAC or VCS on insulin production or gene expression. Moreover, the majority of rodent studies (8,28-39) and previous studies using human islets (7,10,40-47) used concentrations of calcineurin inhibitors that are higher than seen clinically. Our study extends these previous findings by using clinically relevant doses of TAC and VCS, rigorously examining the kinetics of insulin release in human islets and by implicating a direct effect on insulin granule trafficking. TAC at 10 ng/ml (clinical trough) and 20 ng/ml (clinical peak) significantly inhibited total insulin secretion in response to 15 mM glucose and this inhibition was directly due to a specific effect on the 2nd phase of insulin release. Furthermore, KCl-stimulated insulin secretion was decreased to a similar degree, implicating secretory pathways distal to Ca\(^{2+}\) entry via voltage-gated Ca\(^{2+}\) channels. Together, these data suggest that the readily releasable pool of insulin granules is not robustly affected by TAC-mediated calcineurin inhibition; instead, TAC most likely impairs pathways associated with insulin granule trafficking to the plasma membrane. While we did not directly look at exocytotic events in this study, the results of our RNAseq analysis are consistent with a TAC-mediated effect on insulin granule traffic and release. TAC has previously been suggested to impair glucose-stimulated insulin secretion in rat islets via a mechanism involving insulin granule exocytosis (39). Future studies using electrophysiology and imaging to examine insulin granule docking, priming and release will provide a more detailed biophysical explanation of TAC effects in human \(\beta\)-cells.

Our RNAseq data provided novel insights into the molecular mechanisms controlling insulin secretion from human \(\beta\)-cells, the effects of these drugs, and impetus for follow-up studies on
several gene products. A prime candidate is SYT16, which has not previously been directly implicated in glucose-stimulated insulin secretion but that is known to be glucose responsive in human islets (48) and under circadian control in mouse islets (49). The causal role of SYT5 in insulin secretion remains unclear in primary human β-cells (50), but should also be investigated further. TAC likely also has direct effects on insulin granule trafficking given that TBC1D30 is an activating GTPase of RAB3 (51). MLIP activates AKT, which can promote insulin secretion (52), and is regulated by CREB/CREM transcription factors. Indeed, TAC significantly inhibited CREM, a member of the CREB family of transcription factors known as master regulators of β-cell function (53). Previous studies in a β-cell line have shown that TAC inhibits CREB transcriptional activity (54). B9D1 contributes to the biogenesis of the primary cilium, which is required for normal insulin secretion (55). PCK1 and PDK4 regulate cellular metabolism, but require additional studies in human islets. TAC reduced IAPP expression but the functional consequence of this is unclear. Thus, the majority of significantly downregulated genes point to the distal stages of insulin trafficking and exocytosis as the primary sites of TAC-induced β-cell dysfunction. We used protein-protein interaction mapping to predict the most likely link(s) between calcineurin signaling and the TAC-downregulated genes. Indeed, this network analysis suggested direct and robust links to CREM in TAC-treated human islets. Collectively, these data further solidify the role of calcineurin signaling and NFAT-mediated gene transcription in human β-cell function and provide insight into the molecular mechanisms controlling 2nd phase insulin exocytosis.

Calcineurin activity has been ascribed a number of functions in pancreatic β-cells (8-10,41,56-59). For example, cultured insulinoma cells treated with the calcineurin inhibitor cypermethrin exhibited decreased insulin exocytosis in response to both glucose and KCl stimulation (60). In contrast to this, some studies suggest that calcineurin has a negative role in insulin exocytosis. However, these were indirect findings obtained by examining the inhibition of β-cell exocytosis via neurotransmitter-mediated activation of calcineurin (61,62), as opposed to
direct effects observed following inhibition of calcineurin. Nevertheless, our study now shows that VCS is gentler on human islets because it does not cause the same level of inhibition on insulin exocytosis compared to TAC.

In our previous work, we examined the different effects of immunosuppressive drugs (TAC, cyclosporine, and rapamycin) on induced endoplasmic reticulum (ER) stress and caspase-3-dependent apoptosis in human islets (7). In that study, we found that TAC impaired glucose-stimulated insulin release from human islets, but did not significantly elevate the protein levels of CHOP or cleaved caspase-3, indicating that its effects were mostly on β-cell function rather than fate (7). In our current study we measured human islet cell survival over a longer period by using our high-content imaging protocol. We found that neither TAC nor VCS had significant deleterious effect on islet cell survival or insulin content over 48 hours, under the current testing conditions. Similarly, our post RNA-seq pathway analysis did not identify significant changes in genes involved in β-cell apoptosis and/or survival. While an increase in β-cell ER-stress and apoptosis is a plausible pathophysiological mechanism for the diabetic effects of immunosuppressants in the post-transplant clinical setting, it is unlikely that this is the mechanism explaining why the risk of NODAT is higher in patients taking TAC when compared with VCS.

Limitations of our study include the following. Although we had the benefit of directly examining human islets, our in vitro experiments may be impacted by islet isolation and culture. Nevertheless, the fundamental in vivo mechanisms appear to be well conserved in high quality isolated islets such as those used in our study (11). Mechanistically, our analysis of insulin secretion in response to high glucose and high KCl, together with the transcriptomic profiling, points to direct effects on the distal processes of insulin exocytosis. Future studies could directly measure exocytosis with electrophysiological capacitance measurements. Our data point to differences in NFAT activation between VCS and TAC than can explain the distinct impacts on insulin secretion, but our work employed non-β-cells for the dose-finding experiment and ideally
future studies will be repeated in human β-cells or human β-cell lines. We chose the concentrations for our in vitro studies based on clinical efficacy. The observation that lower concentrations of TAC were more toxic than VCS favours this next generation immunosuppressant. Given the clinical importance of calcineurin inhibitor mediated β-cell dysfunction, we hope that our work stimulates more experimentation in human islets and other key tissue governing glucose homeostasis.

In summary, we have demonstrated that TAC, but not VCS, significantly inhibits the total response of glucose-stimulated insulin secretion from human islets. This decrease in secretion is not mediated by effects on islet cell health or insulin content and is most likely a direct consequence of decreased insulin granule exocytosis. VCS, a next generation calcineurin inhibitor, does not cause the same degree of inhibition of insulin secretion. Thus, this is a plausible physiological mechanism explaining the lower incidence of NODAT in patients taking VCS.

Acknowledgments

Human islets for research were provided by the Alberta Diabetes Institute IsletCore at the University of Alberta in Edmonton (http://bcell.org/human-islets) with the assistance of the Human Organ Procurement and Exchange (HOPE) program, Trillium Gift of Life Network (TGLN) and other Canadian organ procurement organizations. Islet isolation was approved by the Human Research Ethics Board at the University of Alberta (Pro00013094). All donors’ families gave informed consent for the use of pancreatic tissue in research and we are grateful for their gift. We thank Xioake Betty Hu for technical assistance.

Author Contributions:

JK designed, conducted and analyzed experiments, and co-wrote the manuscript.

LB conducted and analyzed experiments and edited the manuscript.

PO designed, conducted and analyzed experiments, and edited the manuscript.
HHC designed and analyzed experiments and edited the manuscript.

EP designed, conducted and analyzed experiments, and edited the manuscript.

DRU designed, conducted and analyzed experiments, and edited the manuscript.

JLC designed experiments and edited the manuscript.

RBH designed experiments and edited the manuscript.

JDJ designed and analyzed experiments and co-wrote the manuscript.

Data Availability:

All data generated or analyzed during this study are included in this published article or in the data repositories listed in References.
References

1. Porrini E, Moreno JM, Osuna A, Benitez R, Lampreabe I, Diaz JM, Silva I, Dominguez R, Gonzalez-Cotorruelo J, Bayes B, Lauzurica R, Ibernon M, Moreso F, Delgado P, Torres A. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. *Transplantation*. 2008;85(8):1133-1138.

2. Vincenti F, Friman S, Schneermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy M, Budde K, Goto N, Investigators D. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. *Am J Transplant*. 2007;7(6):1506-1514.

3. Gala-Lopez BL, Pepper AR, Pawlick RL, O’Gorman D, Kin T, Bruni A, Abualhassan N, Bral M, Bautista A, Manning Fox JE, Young LG, MacDonald PE, Shapiro AM. Antiaging Glycopeptide Protects Human Islets Against Tacrolimus-Related Injury and Facilitates Engraftment in Mice. *Diabetes*. 2016;65(2):451-462.

4. Busque S, Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU, Investigators P. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. *Am J Transplant*. 2011;11(12):2675-2684.

5. Rovin BH, Solomons N, Pendergraft WF, 3rd, Dooley MA, Tumlin J, Romero-Diaz J, Lysenko L, Navarra SV, Huizinga RB, Group A-LS. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. *Kidney Int*. 2019;95(1):219-231.

6. Torres A, Hernandez D, Moreso F, Seron D, Burgos MD, Pallardo LM, Kanter J, Diaz Corte C, Rodriguez M, Diaz JM, Silva I, Valdes F, Fernandez-Rivera C, Osuna A, Gracia Guindo MC, Gomez Alamillo C, Ruiz JC, Marrero Miranda D, Perez-Tamajon L, Rodriguez A, Gonzalez-Rinne A, Alvarez A, Perez-Carreno E, de la Vega Prieto MJ, Henriquez F,
Gallego R, Salido E, Porrini E. Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus. Kidney Int Rep. 2018;3(6):1304-1315.

7. Johnson JD, Ao Z, Ao P, Li H, Dai LJ, He Z, Tee M, Potter KJ, Klimek AM, Meloche RM, Thompson DM, Verchere CB, Warnock GL. Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets. Cell Transplant. 2009;18(8):833-845.

8. Heit JJ, Apelqvist AA, Gu X, Winslow MM, Neilson JR, Crabtree GR, Kim SK. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature. 2006;443(7109):345-349.

9. Goodyer WR, Gu X, Liu Y, Bottino R, Crabtree GR, Kim SK. Neonatal beta cell development in mice and humans is regulated by calcineurin/NFAT. Dev Cell. 2012;23(1):21-34.

10. Dai C, Walker JT, Shostak A, Padgett A, Spears E, Wisniewski S, Poffenberger G, Aramandla R, Dean ED, Prasad N, Levy SE, Greiner DL, Shultz LD, Bottino R, Powers AC. Tacrolimus- and sirolimus-induced human beta cell dysfunction is reversible and preventable. JCI Insight. 2020;5(1).

11. Lyon J, Manning Fox JE, Spigelman AF, Kim R, Smith N, O’Gorman D, Kin T, Shapiro AM, Rajotte RV, MacDonald PE. Research-Focused Isolation of Human Islets From Donors With and Without Diabetes at the Alberta Diabetes Institute IsletCore. Endocrinology. 2016;157(2):560-569.

12. Batiuk TD, Pazderka F, Enns J, DeCastro L, Halloran PF. Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. J Clin Invest. 1995;96(3):1254-1260.
13. Kuo J, Bobardt M, Chatterji U, Mayo PR, Trepanier DJ, Foster RT, Gallay P, Ure DR. A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models. *J Pharmacol Exp Ther*. 2019;371(2):231-241.

14. Rezania A, Bruin JE, Arora P, Rubin A, Batushansky I, Asadi A, O'Dwyer S, Quiskamp N, Mojibian M, Albrecht T, Yang YH, Johnson JD, Kieffer TJ. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. *Nat Biotechnol*. 2014;32(11):1121-1133.

15. Yang YH, Szabat M, Bragagnini C, Kott K, Helgason CD, Hoffman BG, Johnson JD. Paracrine signalling loops in adult human and mouse pancreatic islets: netrins modulate beta cell apoptosis signalling via dependence receptors. *Diabetologia*. 2011;54(4):828-842.

16. Alejandro EU, Lim GE, Mehran AE, Hu X, Taghizadeh F, Pelipeychenko D, Baccarini M, Johnson JD. Pancreatic beta-cell Raf-1 is required for glucose tolerance, insulin secretion, and insulin 2 transcription. *Faseb J*. 2011;25(11):3884-3895.

17. Jeffrey KD, Alejandro EU, Luciani DS, Kalnyak TB, Hu X, Li H, Lin Y, Townsend RR, Polonsky KS, Johnson JD. Carboxypeptidase E mediates palmitate-induced beta-cell ER stress and apoptosis. *Proc Natl Acad Sci U S A*. 2008;105(24):8452-8457.

18. Dror V, Kalnyak TB, Bychkivska Y, Frey MH, Tee M, Jeffrey KD, Nguyen V, Luciani DS, Johnson JD. Glucose and endoplasmic reticulum calcium channels regulate HIF-1beta via presenilin in pancreatic beta-cells. *J Biol Chem*. 2008;283(15):9909-9916.

19. Luciani DS, Johnson JD. Acute effects of insulin on beta-cells from transplantable human islets. *Molecular and Cellular Endocrinology*. 2005;241(1-2):88-98.

20. Yang YH, Wills QF, Johnson JD. A live-cell, high-content imaging survey of 206 endogenous factors across five stress conditions reveals context-dependent survival effects in mouse primary beta cells. *Diabetologia*. 2015;58(6):1239-1249.
Yang YH, Vilin YY, Roberge M, Kurata HT, Johnson JD. Multiparameter Screening Reveals a Role for Na(+) Channels in Cytokine-Induced beta-Cell Death. *Molecular endocrinology*. 2014;28(3):406-417.

Yang YH, Manning Fox JE, Zhang KL, MacDonald PE, Johnson JD. Intraislet SLIT-ROBO signaling is required for beta-cell survival and potentiates insulin secretion. *Proc Natl Acad Sci U S A*. 2013;110(41):16480-16485.

Yang YH, Johnson JD. Multi-parameter single-cell kinetic analysis reveals multiple modes of cell death in primary pancreatic beta-cells. *J Cell Sci*. 2013;126(Pt 18):4286-4295.

Dumont FJ. FK506, an immunosuppressant targeting calcineurin function. *Curr Med Chem*. 2000;7(7):731-748.

Sieber M, Baumgrass R. Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506? *Cell Commun Signal*. 2009;7:25.

Braun M, Ramracheya R, Johnson PR, Rorsman P. Exocytotic properties of human pancreatic beta-cells. *Ann N Y Acad Sci*. 2009;1152:187-193.

Xu C, Niu YJ, Liu XJ, Teng YQ, Li CF, Wang HY, Yin JP, Wang LT, Shen ZY. Tacrolimus reversibly reduces insulin secretion, induces insulin resistance, and causes islet cell damage in rats. *Int J Clin Pharmacol Ther*. 2014;52(7):620-627.

Ozbay LA, Smidt K, Mortensen DM, Carstens J, Jorgensen KA, Rungby J. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. *Br J Pharmacol*. 2011;162(1):136-146.

Radu RG, Fujimoto S, Mukai E, Takehiro M, Shimono D, Nabe K, Shimodahira M, Kominato R, Aramaki Y, Nishi Y, Funakoshi S, Yamada Y, Seino Y. Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity. *Am J Physiol Endocrinol Metab*. 2005;288(2):E365-371.
30. Paty BW, Harmon JS, Marsh CL, Robertson RP. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. Transplantation. 2002;73(3):353-357.

31. Redmon JB, Olson LK, Armstrong MB, Greene MJ, Robertson RP. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest. 1996;98(12):2786-2793.

32. Ishizuka J, Gugliuzza KK, Wassmuth Z, Hsieh J, Sato K, Tsuchiya T, Townsend CM, Jr., Fish JC, Thompson JC. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. Transplantation. 1993;56(6):1486-1490.

33. Wakugami T, Islam MR, Higa S, Murakami K, Mimura G. Effect of FK506 on the development of diabetes in BB rats in comparison with that of cyclosporin. Tohoku J Exp Med. 1993;169(1):21-29.

34. Herold KC, Nagamatsu S, Buse JB, Kulsakdinun P, Steiner DF. Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. Transplantation. 1993;55(1):186-192.

35. Carroll PB, Goncalves AA, Boschero AC, Tzakis AG, Starzl TE, Atwater I. Effect of the immunosuppressant FK 506 on insulin release from adult rat islets of Langerhans. Transplant Proc. 1991;23(1 Pt 1):337-339.

36. Rostambeigi N, Lanza IR, Dzeja PP, Deeds MC, Irving BA, Reddi HV, Madde P, Zhang S, Asmann YW, Anderson JM, Schimke JM, Nair KS, Eberhardt NL, Kudva YC. Unique cellular and mitochondrial defects mediate FK506-induced islet beta-cell dysfunction. Transplantation. 2011;91(6):615-623.

37. Hernandez-Fisac I, Pizarro-Delgado J, Calle C, Marques M, Sanchez A, Barrrientos A, Tamarit-Rodriguez J. Tacrolimus-induced diabetes in rats courses with suppressed insulin gene expression in pancreatic islets. Am J Transplant. 2007;7(11):2455-2462.
38. Uchizono Y, Iwase M, Nakamura U, Sasaki N, Goto D, Iida M. Tacrolimus impairment of insulin secretion in isolated rat islets occurs at multiple distal sites in stimulus-secretion coupling. *Endocrinology*. 2004;145(5):2264-2272.

39. Kloster-Jensen K, Sahraoui A, Vethe NT, Korsgren O, Bergan S, Foss A, Scholz H. Treatment with Tacrolimus and Sirolimus Reveals No Additional Adverse Effects on Human Islets In Vitro Compared to Each Drug Alone but They Are Reduced by Adding Glucocorticoids. *J Diabetes Res*. 2016;2016:4196460.

40. Soleimanpour SA, Crutchlow MF, Ferrari AM, Raum JC, Groff DN, Rankin MM, Liu C, De Leon DD, Naji A, Kushner JA, Stoffers DA. Calcineurin signaling regulates human islet (beta)-cell survival. *J Biol Chem*. 2010;285(51):40050-40059.

41. Bugliani M, Masini M, Liechti R, Marselli L, Xenarios I, Boggi U, Filipponi F, Masiello P, Marchetti P. The direct effects of tacrolimus and cyclosporin A on isolated human islets: A functional, survival and gene expression study. *Islets*. 2009;1(2):106-110.

42. Polastri L, Galbiati F, Bertuzzi F, Fiorina P, Nano R, Gregori S, Aldrighetti L, Pozza G, Secchi A, Adorini L, Davalli AM. Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells. *Acta Diabetol*. 2002;39(4):229-233.

43. Ricordi C, Zeng Y, Alejandro R, Tzakis A, Carroll P, Rilo HL, Venkataramanan R, Fung JJ, Bereiter D, Starzl TE. Effect of FK 506 on human pancreatic islets following renal subcapsular transplantation in diabetic nude mice. *Transplant Proc*. 1992;24(3):1042.

44. Ricordi C, Zeng YJ, Alejandro R, Tzakis A, Venkataramanan R, Fung J, Bereiter D, Mintz DH, Starzl TE. In vivo effect of FK506 on human pancreatic islets. *Transplantation*. 1991;52(3):519-522.

45. Tze WJ, Tai J, Cheung S. In vitro effects of FK-506 on human and rat islets. *Transplantation*. 1990;49(6):1172-1174.

46. Trinanes J, Ten Dijke P, Groen N, Hanegraaf M, Porrini E, Rodriguez-Rodriguez AE, Drachenberg C, Rabelink TJ, de Koning E, Carlotti F, de Vries APJ. Tacrolimus-Induced
BMP/SMAD Signaling Associates With Metabolic Stress-Activated FOXO1 to Trigger beta-Cell Failure. *Diabetes*. 2020;69(2):193-204.

47. Hall E, Dekker Nitert M, Volkov P, Malmgren S, Mulder H, Bacos K, Ling C. The effects of high glucose exposure on global gene expression and DNA methylation in human pancreatic islets. *Mol Cell Endocrinol*. 2018;472:57-67.

48. Perelis M, Marcheva B, Ramsey KM, Schipma MJ, Hutchison AL, Taguchi A, Peek CB, Hong H, Huang W, Omura C, Allred AL, Bradfield CA, Dinner AR, Barish GD, Bass J. Pancreatic beta cell enhancers regulate rhythmic transcription of genes controlling insulin secretion. *Science*. 2015;350(6261):aac4250.

49. Andersson SA, Olsson AH, Esguerra JL, Heimann E, Ladenvall C, Edlund A, Salehi A, Taneera J, Degerman E, Groop L, Ling C, Eliasson L. Reduced insulin secretion correlates with decreased expression of exocytotic genes in pancreatic islets from patients with type 2 diabetes. *Mol Cell Endocrinol*. 2012;364(1-2):36-45.

50. Regazzi R, Ravazzola M, Iezzi M, Lang J, Zahraoui A, Andereggen E, Morel P, Takai Y, Wollheim CB. Expression, localization and functional role of small GTPases of the Rab3 family in insulin-secreting cells. *J Cell Sci*. 1996;109 (Pt 9):2265-2273.

51. Bernal-Mizrachi E, Fatrai S, Johnson JD, Ohsugi M, Otani K, Han Z, Polonsky KS, Permutt MA. Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet beta cells. *J Clin Invest*. 2004;114(7):928-936.

52. Blanchet E, Van de Velde S, Matsumura S, Hao E, LeLay J, Kaestner K, Montminy M. Feedback inhibition of CREB signaling promotes beta cell dysfunction in insulin resistance. *Cell Rep*. 2015;10(7):1149-1157.

53. Oetjen E, Thoms KM, Laufer Y, Pape D, Blume R, Li P, Kneipel W. The immunosuppressive drugs cyclosporin A and tacrolimus inhibit membrane depolarization-
induced CREB transcriptional activity at the coactivator level. *Br J Pharmacol.* 2005;144(7):982-993.

54. Hughes JW, Cho JH, Conway HE, DiGruccio MR, Ng XW, Roseman HF, Abreu D, Urano F, Piston DW. Primary cilia control glucose homeostasis via islet paracrine interactions. *Proc Natl Acad Sci U S A.* 2020;117(16):8912-8923.

55. Li X, Chan LWC, Li X, Liu C, Yang G, Gao J, Dai M, Wang Y, Xie Z, Liu J, Zhou F, Zheng T, Feng D, Guo S, Li H, Sun K, Yang S. Obesity-Induced Regulator of Calcineurin 1 Overexpression Leads to beta-Cell Failure Through Mitophagy Pathway Inhibition. *Antioxid Redox Signal.* 2020;32(7):413-428.

56. Zhao J, Zong W, Zhao Y, Gou D, Liang S, Shen J, Wu Y, Zheng X, Wu R, Wang X, Niu F, Wang A, Zhang Y, Xiong JW, Chen L, Liu Y. In vivo imaging of beta-cell function reveals glucose-mediated heterogeneity of beta-cell functional development. *Elife.* 2019;8.

57. Alejandro EU, Kalynyak TB, Taghizadeh F, Gwiazda KS, Rawstron EK, Jacob KJ, Johnson JD. Acute insulin signaling in pancreatic beta-cells is mediated by multiple Raf-1 dependent pathways. *Endocrinology.* 2010;151(2):502-512.

58. Bernal-Mizrachi E, Cras-Meneur C, Ye BR, Johnson JD, Permutt MA. Transgenic overexpression of active calcineurin in beta-cells results in decreased beta-cell mass and hyperglycemia. *PLoS One.* 2010;5(8):e11969.

59. Wang R, McGrath BC, Kopp RF, Roe MW, Tang X, Chen G, Cavener DR. Insulin secretion and Ca2+ dynamics in beta-cells are regulated by PERK (EIF2AK3) in concert with calcineurin. *J Biol Chem.* 2013;288(47):33824-33836.

60. Renstrom E, Ding WG, Bokvist K, Rorsman P. Neurotransmitter-induced inhibition of exocytosis in insulin-secreting beta cells by activation of calcineurin. *Neuron.* 1996;17(3):513-522.
Braun M, Wendt A, Buschard K, Salehi A, Sewing S, Gromada J, Rorsman P. GABAB receptor activation inhibits exocytosis in rat pancreatic beta-cells by G-protein-dependent activation of calcineurin. *J Physiol*. 2004;559(Pt 2):397-409.
Figure Legends

Figure 1| Experimental design, and human islet donor and isolation characteristics (A) 
Experimental design for study of VCS and TAC effects on high quality primary human islets isolated from cadaveric donors. Details of each isolation are available from IsletCore.ca (the example image shown from the R297 isolation). (B) High-quality, research-specific human islets from consenting donors were obtained from IsletCore Laboratory in Edmonton, Alberta. Islet donors and isolation characteristics are listed here. Stimulation index is the average of 3 technical replicates of the 16.7 mM to 2.8 mM glucose response as provided by the IsletCore Laboratory quality control database.

Figure 2| Differences between TAC, VCS and CsA on calcineurin activity, lymphocyte proliferation assay, and NFAT accumulation. (A-D) Sister aliquots of PBMC were treated in the presence of drug or vehicle control for analysis of lymphocyte cell division (Div), calcineurin activity (CN), and cytosolic NFAT. (A) Lymphocyte division was determined by CFSE analysis following 3-day stimulation with CD3 antibody. Calcineurin activity was determined by radioactive 32P-RII peptide assay following 30-min stimulation with PMA+A23187. (B) Cytosolic NFAT relative to CypA (loading control protein) was determined by Western blotting and densitometric quantitation following 30-min stimulation with PMA+A23187. (C) K562 cells stably transfected with an NFAT-luciferase reporter were stimulated for 22 hr with PMA + A23187 in the presence of drug or vehicle control. Cells were separated into separate aliquots for measurement of calcineurin activity and luciferase activity for NFAT promoter activation. (D) Percent inhibition was determined by normalizing values to vehicle control (100% activity) and to 2 µg/ml VCS (100% inhibition). These observations were replicated 5 times. (E) Calculated IC50 values in PBMC and K562-NFAT-Luc. n = 8-12 experiments for PBMC and 4-7 experiments for K562-NFAT-Luc.
Figure 3| Basal, glucose-stimulated and KCl-stimulated insulin secretion from human islets treated with peak and trough concentrations of VCS and TAC. (A) Averaged traces of dynamic insulin secretion measurements in the context of 3 mM glucose, 15 mM glucose, or 30 mM KCl (as indicated). (B) Total area under the curve (AUC) of the 15 mM glucose response. (C, D, E) AUCs of 1st phase and 2nd phase 15 mM glucose responses, as well as the KCl response. (F) Baseline insulin secretion. (G, H) Insulin secretion normalized to baseline, including AUC. n=17

Figure 4| Insulin content from isolated human islets treated with VCS and TAC. Insulin protein measured by radioimmunoassay from 20 islets treated for 48 hours with VCS or TAC (concentrations as indicate) after acid-ethanol extraction of insulin.

Figure 5| Islet cell survival from dispersed human islets treated with VCS and TAC. (A,B) Cell death was assessed every 30 minutes over 48 hours using Propidium Iodide (PI) and Hoechst staining, with a significant increase seen in the presence of a β-cell toxic cytokine cocktail. (C) Shown is the maximum cell death normalized measurement (see methods) for each condition TAC and VCS dose, normalized to the DMSO control cultures. Results shown are quantified from 5 cultures per drug condition, over two separate runs.

Figure 6| RNA sequencing analysis and protein-protein interaction networks of human islets treated with TAC and VCS at peak doses. (A) mRNAs that were nominally differentially expressed (adjusted p < 0.05) are shown (B) Protein-protein interaction networks highlight connections between calcineurin/NFAT pathway and deferentially expression genes in (A) VCS or (B) TAC treatment. Up or down regulated genes are shown in red or green, respectively.
Figure 7| Working model of differential regulation of insulin exocytosis by VCS and TAC.

In our model, TAC has more potent inhibitory effects on NFAT, and therefore results in the stronger suppression of key genes. TAC-sensitive gene products with known functions related to insulin secretion are shown in orange.
**Overall study design and human islet donor characteristics**

**A**

![Diagram of human islet isolation and culture](image)

**B**

| Donor ID | Age (years) | Sex | HbA1c (%) | BMI | Islet Purity | Stimulation Index | Experiments |
|----------|-------------|-----|-----------|-----|--------------|------------------|-------------|
| R297     | 69          | Male | No data   | 27.2| 90%          | 5.05             | Perifusion   |
| R300     | 30          | Female | No data   | 25.3| 75%          | 2.05             | Perifusion   |
| R301     | 18          | Male | 5.0       | 19.0| 75%          | 9.21             | Perifusion   |
| R302     | 62          | Female | 6.2       | 32.3| 40%          | 3.57             | RNAseq      |
| R303     | 56          | Female | No data   | 24.1| 85%          | 2.64             | Perifusion   |
| R305     | 60          | Male | 5.6       | 21.0| 80%          | 1.29             | Perifusion, RNAseq |
| R306     | 22          | Female | 5.3       | 21.1| 80%          | 19.13            | Perifusion   |
| R308     | 20          | Male | 5.5       | 19.8| 80%          | 5.90             | Perifusion   |
| R309     | 47          | Female | 5.5       | 27.4| 80%          | 9.08             | Perifusion, RNAseq |
| R310     | 25          | Male | 5.4       | 26.4| 90%          | 3.81             | Perifusion, RNAseq |
| R314     | 31          | Female | 5.0       | 30.3| 80%          | 6.53             | Perifusion, RNAseq |
| R316     | 52          | Male | 5.7       | 26.0| 50%          | 6.93             | Perifusion, RNAseq |
| R317     | 54          | Male | 5.1       | 26.4| 90%          | 10.78            | RNAseq      |
| R318     | 54          | Male | 5.0       | 20.5| 90%          | 2.76             | Perifusion   |
| R319     | 68          | Male | 5.0       | 27.8| 90%          | 5.04             | Perifusion   |
| R322     | 44          | Female | 4.9       | 23.2| 90%          | 3.09             | Perifusion   |
| R325     | 50          | Male | No data   | 30.3| 75%          | 2.86             | Perifusion   |
| R326     | 26          | Male | 5.5       | 27.0| 90%          | 5.34             | Perifusion   |
| R327     | 57          | Male | 5.8       | 33.9| 95%          | 3.59             | Perifusion   |
| R335     | 25          | Male | 4.9       | 24.6| 80%          | 11.92            | Cell death   |
| R338     | 30          | Male | 5.3       | 25.5| 90%          | 6.73             | Cell death   |
Figure 2

A

B

C

D

E

|               | PBMC Calcineurin Activity | PBMC Cell Division | K562-NFAT-Luc Calcineurin Activity | K562-NFAT-Luc NFAT Activity |
|---------------|----------------------------|--------------------|-----------------------------------|----------------------------|
| IC50 (±SE)    | Relative Potency           | IC50 (±SE)         | Relative Potency                  | IC50 (±SE)                 | Relative Potency |
| CsA           | 83.7 (±18.7)               | 1                  | 50.5 (±7.8)                       | 1                          | 201.6 (±52.7)    | 1                  |
| VCS           | 26.3 (±4.1)                | 3.2                | 13.8 (±2.1)                       | 3.7                        | 65.2 (±15.9)     | 3.1                |
| TAC           | 2.6 (±0.7)                 | 32                 | 0.3 (±0.2)                        | 168                        | 1.1 (±0.3)       | 183                |
|               |                            |                    |                                   |                            | 0.054 (±0.02)     | 989                |
Figure 4

A

Total Insulin Content (µU/ml) per 20 islets

- DMSO
- VCS - 20 ng/ml
- VCS - 60 ng/ml
- TAC - 10 ng/ml
- TAC - 30 ng/ml

ns
Figure 5

A

PI positive cells (% total cells) after 48 hours

- + Cytokine
- - Cytokine

B

PI positive cells (% total cells) after 48 hours

C

% Death after 48 hours

VCS (ng/ml)

1 10 20 30 60 120

TAC (ng/ml)

1 10 20 30 60 120

ns
Figure 6

A

|     | Control | TAC     | VCS     |
|-----|---------|---------|---------|
| SYT6|         |         |         |
| TBC1D30 |       |         |         |
| PCK1 |         |         |         |
| SMOC1|         |         |         |
| SYT5 |         |         |         |
| MLIP |         |         |         |
| CCDC184|       |         |         |
| ASB4 |         |         |         |
| PDK4 |         |         |         |
| LINC00473|     |         |         |
| LINC00602|     |         |         |
| SLC8A1-AS1|    |         |         |
| LGI2 |         |         |         |
| IAPP |         |         |         |
| CREM |         |         |         |
| B9D1 |         |         |         |
| SCARB2|        |         |         |

TAC vs Control

|     | p value |
|-----|---------|
| SYT6| 1.10E-10|
| TBC1D30 | 1.82E-10|
| PCK1 | 1.33E-09|
| SMOC1| 1.12E-05|
| SYT5 | 0.000112|
| MLIP | 0.000114|
| CCDC184| 0.000136|
| ASB4 | 0.00014 |
| PDK4 | 0.000229|
| LINC00473| 0.00032 |
| LINC00602| 0.001004|
| SLC8A1-AS1| 0.001004|
| LGI2 | 0.00231 |
| IAPP | 0.008569|
| CREM | 0.031832|
| B9D1 | 0.03586 |
| SCARB2| 0.045787|

VCS vs Control

|     | p value |
|-----|---------|
| SYT6| 1.65E-07|
| TBC1D30 | 1.76E-07|
| PCK1 | 0.002288|

B

Differentially expressed genes

TAC vs DMSO

Calcineurin/NFAT Network
